Clinical trials in ALS: what did we learn from recent trials in humans?

Area of Science:

• Neurology
• Clinical Trials
• Neurodegenerative Diseases

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with no cure.
• Current treatment strategies focus on managing symptoms and improving quality of life.
• Understanding prognostic factors is crucial for effective disease management and clinical trial design.

Purpose of the Study:

• To develop a prognostic score for amyotrophic lateral sclerosis (ALS) using clinical parameters.
• To assess the utility of this score in clinical practice and therapeutic trial design.
• To review current ALS clinical trial endpoints and identify discrepancies in efficacy measures.

Main Methods:

• A prognostic score was developed using data from a large population of ALS patients in the Phase IV Rilutek Trial in France.
• Key prognostic variables identified include vital capacity, spasticity, fasciculations, swallowing, cough, and creatininemia.
• A literature review of recent ALS clinical trials was conducted to analyze efficacy endpoints.

Main Results:

• A bedside clinical prognostic score for ALS was developed and validated.
• The score incorporates easily assessable clinical parameters and is useful for disease management and trial planning.
• Analysis of recent trials revealed a discrepancy between drug effects on survival and functional outcomes.

Conclusions:

• The developed prognostic score is a valuable tool for managing amyotrophic lateral sclerosis (ALS) and designing clinical trials.
• A reappraisal of strategies for identifying therapeutic targets in ALS is necessary.
• Further research is needed to reconcile survival and functional endpoints in ALS clinical trials.